|
Originally published In Press as doi:10.1074/jbc.M200724200 on April 23, 2002
J. Biol. Chem., Vol. 277, Issue 26, 23958-23964, June 28, 2002
Nuclear Import Strategies of High Risk HPV16 L1 Major Capsid
Protein*
Lisa M.
Nelson ,
Robert C.
Rose§, and
Junona
Moroianu ¶
From the Biology Department, Boston College, Chestnut
Hill, Massachusetts 02467 and the § Department of Medicine
and Microbiology and Immunology, University of Rochester School of
Medicine and Dentistry, Infectious Diseases Unit, Rochester, New York
14642
Received for publication, January 23, 2002, and in revised form, March 22, 2002
 |
ABSTRACT |
During the late phase of human papillomavirus
(HPV) infection, the L1 major capsid proteins enter the nuclei of host
epithelial cells and, together with the L2 minor capsid proteins,
assemble the replicated viral DNA into virions. We investigated the
nuclear import of the L1 major capsid protein of high risk HPV16. When digitonin-permeabilized HeLa cells were incubated with HPV16 L1 capsomeres, the L1 protein was imported into the nucleus in a receptor-mediated manner. HPV16 L1 capsomeres formed complexes with Kap
2 1 heterodimers via interaction with Kap 2. Accordingly, nuclear import of HPV16 L1 capsomeres was mediated by Kap 2 1 heterodimers, required RanGDP and free GTP, and was independent of GTP
hydrolysis. Remarkably, HPV16 L1 capsomeres also interacted with Kap
2 and binding of RanGTP to Kap 2 did not dissociate the HPV16
L1·Kap 2 complex. Significantly, HPV16 L1 capsomeres inhibited the nuclear import of Kap 2 and of a Kap 2-specific M9-containing cargo. These data suggest that, during the productive stage of infection, while the HPV16 L1 major capsid protein enters the
nucleus via the Kap 2 1-mediated pathway to assemble the virions,
it also inhibits the Kap 2-mediated nuclear import of host hnRNP A1
protein and, in this way, favors virion formation.
 |
INTRODUCTION |
Human papillomaviruses
(HPVs)1 are thought to be the
primary causative agent in more than 90% of all cervical cancers, with HPV16 being the type most frequently found in these tumors.
Approximately 500,000 new cases of cervical cancer are identified each
year globally with nearly 300,000 deaths annually. About 85 genotypically distinct HPV genotypes have been isolated and
characterized, with roughly half infecting the skin and the other half
preferentially infecting oral/anogenital mucosal epithelial tissues.
Mucosal HPVs have demonstrated varying degrees of oncogenic potential; high risk HPVs, such as types 16, 18, 31, and 45, are frequently detected in invasive cervical carcinomas, whereas the low risk types,
such as types 6 and 11, are more often associated with benign exophytic
condylomas (1).
HPVs are small, nonenveloped, icosahedral DNA viruses that replicate in
the nucleus of squamous epithelial cells. The virion particles (52-55
nm in diameter) consist of a single molecule comprising 8 kb of
double-stranded circular DNA contained within a spherical capsid
composed of 72 homopentameric L1 capsomeres and of L2 minor capsid
protein. The number of L2 molecules per capsid has been estimated at 36 (2) or 12 (3). L1 protein is capable of self-assembly both in
vivo and in vitro into capsid-like structures, referred
to as virus-like particles (4-9). L1 is stable in two oligomeric
configurations: homopentameric capsomeres and capsids composed of 72 capsomeres. The capsids can be disassembled into capsomeres
quantitatively by an agent that reduces disulfide bonds and reassembled
by removing the reducing agent (10, 11). The L1 capsid proteins of HPVs
seem to enter the nucleus of host cells twice during the virus life
cycle: immediately after the virions infect the undifferentiated
proliferating epithelial cells and again during the late productive
phase when the newly synthesized L1 and L2 proteins assemble the
replicated HPV genomic DNA into infectious virions inside the nuclei of
terminally differentiated epithelial cells.
Proteins must carry nuclear localization signals (NLSs) to enter
the nucleus. The first identified NLSs, now referred to as classic
NLSs, fall into two categories: a monopartite NLS consisting of a
simple sequence of 3-5 basic amino acid residues and a bipartite NLS
consisting of a basic dipeptide upstream from a simple basic sequence.
Other types of NLSs have since been identified in hnRNP proteins,
ribosomal proteins, and U small nuclear RNPs. NLSs are recognized by adapters of the karyopherin /importin (Kap /Imp ) family and by import receptors of the karyopherin /importin (Kap /Imp ) family that shuttle between the nucleus and the cytoplasm. The basic paradigm for nuclear import is that the NLS cargo
is bound (either directly or indirectly via an adapter) by an import
receptor in the cytoplasm, translocated through the nuclear pore
complex (NPC) and released inside the nucleus. The receptor and the
adapter are then recycled back to the cytoplasm in a form competent for
another round of import (12-14). The first identified nuclear import
receptor was Kap 1, which functions together with a Kap adapter
in nuclear import of proteins that contain classic monopartite or
bipartite NLSs. Kap binds to the NLS of the cargo, whereas Kap 1
mediates docking at the NPC (15-21). There are six human Kap adapters, and it is likely that they have both distinct and overlapping
specificities for classic basic NLSs. Kap 1 can also function
without adapters when importing ribosomal proteins, cyclin B1,
and viral proteins. Other members of the Kap family have been
identified and shown to function in nuclear import of specific cargoes.
All Kap receptors shuttle between the nucleus and the cytoplasm and
bind to nucleoporins at the NPC and to the GTPase Ran in its
GTP-bound form. The nucleotide state of Ran is regulated by cytoplasmic
RanGAP and RanBP1, which accelerate GTP hydrolysis to form
cytoplasmic RanGDP, and by the nuclear RanGEF (RCC1), which catalyzes
nucleotide exchange to regenerate nuclear RanGTP. Binding of nuclear
RanGTP to Kap s (importins) causes the dissociation of the import
complexes with release of the cargoes inside the nucleus. The Kap s
(importins/exportins) exit the nucleus in complex with RanGTP and,
therefore, constantly deplete Ran from the nucleus (12-14). Ran is
actively re-imported into the nucleus via the transport factor
p10/NTF2, which binds specifically to RanGDP but not to RanGTP
(22).
In this study we investigated the nuclear import of the L1 major capsid
protein of high risk HPV16. We found that HPV16 L1 capsomeres enter the
nucleus via the classic Kap 2 1-mediated nuclear import pathway.
Importantly, we also discovered that both HPV16 and HPV45 L1 capsomeres
interact with Kap 2 and inhibit nuclear import of Kap 2 and its
specific M9-containing cargo. These data suggest that during the late
productive stage of infection the newly synthesized L1 major capsid
proteins can interact with Kap 2 and may inhibit major Kap
2-mediated nuclear import pathways and, thus, inhibit other nuclear
events so as to optimize virion formation.
 |
EXPERIMENTAL PROCEDURES |
Preparation of Recombinant Human Nuclear Import
Factors--
His-tagged Kap 2 (20), His-tagged Kap 1 (23), and
His-tagged p10 (18) were expressed in Escherichia coli
BL21(DE3) (3-h induction with 2 mM IPTG at 30 °C), and
the soluble His-tagged proteins were purified in their native state on
Talon beads using a standard procedure. GST-Kap 1 (23) and GST-Kap
2 (24) were expressed in E. coli BL21(DE3) (3-h induction
with 1 mM IPTG at 30 °C), and the soluble GST fusion
proteins were purified in their native state on glutathione-Sepharose
beads using a standard procedure. To obtain cleaved Kap 2, the
GST-Kap 2 fusion protein was incubated for 2 h at room
temperature with a Tev enzyme that has a His tag (Invitrogen),
and after cleavage the GST was removed by binding to
glutathione-Sepharose beads and the Tev enzyme by binding to Talon
beads, using standard procedures. Human Ran (25) was prepared as
described previously (26). All proteins were checked for purity and
lack of proteolytic degradation by SDS-PAGE and Coomassie Blue
staining. The purified proteins were dialyzed in buffer A (20 mM HEPES-KOH, pH 7.3, 110 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 2 mM dithiothreitol) containing protease inhibitors and
stored in aliquots at 80 °C until use.
Preparation of Recombinant HPV16 L1 Capsids and
Capsomeres--
The L1 capsids of HPV16 and HPV45 were generated in
insect cells, purified as described (27, 28), and stored at 4 °C
until use. Purity and lack of proteolytic degradation of the L1
proteins were always checked by SDS-PAGE, Coomassie Blue staining, and immunoblotting prior to use. L1 capsomeres were obtained by incubating the L1 capsids with 5% mercaptoethanol overnight at 4 °C (11).
Antibodies--
Rabbit polyclonal antiserum was raised against
HPV16 L1 capsids as described (27, 28). Murine antibodies raised
against Kap 2/Rch-1 and Kap 2/transportin were from Transduction
Laboratories; a mouse monoclonal antibody to Kap 1/p97 was from
Affinity Bioreagents, Inc., and the goat anti-GST antibody was from
Amersham Biosciences. HeLa cytosol from Cellex Biosciences Inc.
was centrifuged and stored in aliquots at 80 °C.
Preparation of GST-NLSHPV16L1 Fusion
Proteins--
The L1 major capsid protein of HPV16 contains two
classic NLSs at its C terminus: a monopartite NLS (AKRKKRKL) and a
bipartite type that overlaps with the monopartite NLS
(KRKATPTTSSTSTTAKRKKRKL) (29). The monopartite NLS (mpNLS) of HPV16 L1
and the overlapping bipartite/monopartite NLS (bpNLS) of HPV16 L1 were
separately fused to a GST reporter protein. For making the GST-bpNLS
construct the forward and reverse oligonucleotides, phosphorylated at
5'-ends, were annealed, and the overhanging areas were filled in using a DNA polymerase I, large Klenow fragment. The resulting DNA fragments were blunt end-ligated with T4 DNA ligase, double-digested with EcoRI and XhoI, and inserted into pGEX4T-1
(Amersham Biosciences) that was double cut with the same enzymes. For
making the GST-mpNLS construct, unphosphorylated oligonucleotides were
designed with the corresponding restriction-cutting sites, annealed,
and inserted directly into the pGEX4T-1 vector as described above. The
GST-bpNLS and GST-mpNLS constructs were transformed in XL1 blue
bacteria and confirmed by automated sequence analysis (BioServe
Biotechnologies Sequencing Department). The M9-GST construct was a gift
from Dr. Gideon Dreyfuss. For protein expression, the constructs were
used to transform E. coli BL21(DE3) bacteria. After
induction of E. coli BL21(DE3) with 1 mM IPTG
for 3 h at 37 °C, the GST-NLS fusion proteins were purified in
their native state on glutathione-Sepharose using a standard procedure.
The purified proteins were checked by SDS-PAGE and Coomassie Blue
staining, dialyzed in buffer A, and stored in aliquots at 80 °C
until use.
In Vitro Nuclear Import Assays--
Digitonin-permeabilized HeLa
cells have been extensively used by many laboratories to investigate
different nuclear import pathways mediated by mammalian Kap
s/importins (20, 22, 30-38). HeLa cells are cervical carcinoma
cells that contain HPV18 DNA integrated into the cellular genome with
consequent disruption of several viral genes but preservation of the
E6 and E7 genes. Although HeLa cells are
HPV18-positive, this does not affect the import properties of their
nuclear pore complexes, as demonstrated by the fact that the majority
of nuclear import pathways have been identified and characterized with
HeLa cells (20, 22, 30-38). We have previously used these in
vitro nuclear import assays in HeLa cells to investigate import of
HPV11 L1 and HPV45 L1 major capsid proteins (38, 39). In the present
study, subconfluent HeLa cells, grown on
poly-L-lysine-coated glass coverslips for 24 h, were
permeabilized with 70 µg/ml digitonin for 5 min on ice and washed
with buffer A. Digitonin permeabilizes the plasma membrane but leaves
the nuclear envelope intact. As a consequence, digitonin-permeabilized
HeLa cells retain intact import-competent nuclei but are largely
depleted of cytosolic transport factors, as indicated by the absence of
NLS-mediated nuclear import in the presence of buffer alone and in the
absence of either exogenous cytosol or recombinant Kaps plus RanGDP. It
should be noted that p10 is retained in the digitonin-permeabilized
HeLa cells in sufficient amounts to support NLS-mediated nuclear import
(Refs. 32, 34, and 35 and Fig. 2). Unless otherwise specified all
import reactions contained the energy-regenerating system (0.5 mM GTP, 5 mM phosphocreatine, and 0.4 unit of
creatine phosphokinase), plus various transport factors (1 µM Kap 2, 0.5 µM Kap 1, 0.5 µM Kap 2, 3 µM RanGDP, 0.2 µM p10), plus the L1 capsomeres (0.25 µM),
or the GST-NLS fusion proteins (0.5 µM). Final import
reaction volume was adjusted to 20 µl with buffer A. For
visualization of nuclear import, the HPV16 L1 protein and the GST-NLS
fusion proteins were detected by immunofluorescence with specific
antibodies, as previously described (38). The nuclei were identified by
DAPI staining. Nuclear import was analyzed with a Nikon Eclipse TE 300 microscope, which has a fluorescence attachment, and a Sony DKC-5000
charge-coupled device camera.
In-solution Binding Assays--
Two types of binding assays were
performed. First, GST-NLSHPV16L1 fusion proteins,
immobilized on glutathione-Sepharose beads (2 µg of protein/10 µl
of beads) were incubated under rotation for 30 min at room temperature
with the purified Kaps (2 µg of protein) in buffer A (total volume,
40 µl). Control experiments for binding specificity consisted of
incubating GST immobilized on glutathione-Sepharose beads with the
purified Kaps. After incubation, the beads were washed three times with
buffer A, and the bound proteins were eluted with SDS-PAGE sample
buffer and analyzed by SDS-PAGE followed by Coomassie Blue staining.
Second, GST-Kap 1 or GST-Kap 2 immobilized on
glutathione-Sepharose beads (2 µg of protein/10 µl of beads) was
incubated for 30 min under rotation at room temperature with HPV16 L1
or HPV45 L1 capsomeres (2 µg of protein) in buffer A containing
0.25% Tween 20 (binding buffer). In some experiments, 2 µg of either Kap 2 or RanGTP was added to the incubation mixture, as indicated in
the figure legends. Control experiments for binding specificity consisted of incubating GST immobilized on glutathione-Sepharose beads
with the L1 capsomeres. The bound proteins were eluted with SDS-PAGE
sample buffer and analyzed by SDS-PAGE followed by Coomassie Blue staining.
 |
RESULTS |
Disassembly of L1 Capsids Is Required for Nuclear Import of HPV16
L1 Major Capsid Protein--
We had previously established for the L1
major capsid proteins of HPV11 and HPV45 that capsid disassembly is
required for their nuclear import (38, 39). Therefore, the nuclear
import of the L1 major capsid protein of HPV16 was investigated in
either capsid or capsomere conformation. Digitonin-permeabilized
HeLa cells were incubated with either HPV16 L1 capsomeres (Fig.
1A) or HPV16 L1 capsids (Fig. 1B) in the
presence of cytosol and an energy-regenerating system. As previously
found for HPV11 and HPV45, the HPV16 L1 capsomeres were imported into
the nuclei of digitonin-permeabilized cells in the presence of cytosol
(Fig. 1A), whereas the HPV16
L1 capsids were not (Fig. 1B).

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 1.
Nuclear import of HPV16 L1 capsomeres.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with HPV16 L1 capsomeres (A) or HPV16 L1 capsids
(B) in the presence of HeLa cytosol and an
energy-regenerating system. L1 proteins were detected by
immunofluorescence with specific antibodies. Note the nuclear import in
panel A.
|
|
HPV16 L1 Major Capsid Protein Enters the Nucleus via the Kap
2 1-mediated Pathway--
It has been shown previously that the
L1 major capsid protein of HPV16 contains two classic NLSs at the C
terminus: a monopartite NLS and a bipartite type that overlaps with the
monopartite NLS (29). Because HPV16 L1 contains classic basic NLSs, we
investigated whether nuclear import of HPV16 L1 major capsid protein
can be mediated by the Kap 2 1 heterodimers.
Digitonin-permeabilized HeLa cells were incubated with HPV16 L1
capsomeres in the presence of either Kap 1 + RanGDP (A),
Kap 1 + RanGDP + p10 (B), Kap 1 + Kap 2 + RanGDP
(C), or Kap 1 + Kap 2 + RanGDP + p10 (D). We found that nuclear import of HPV16 L1 was efficiently mediated by
Kap 2 1 heterodimers (Fig. 2,
C and D) but not by Kap 1 (Fig. 2,
A and B). Addition of exogenous p10 did not
increase nuclear import of HPV16 L1 capsomeres in agreement with
previous results that sufficient endogenous p10 is retained in the
digitonin-permeabilized HeLa cells to support NLS-mediated import (32,
34, 35).

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 2.
Nuclear import of HPV16 L1 major capsid
protein can be mediated by Kap
2 1 heterodimers.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with HPV16 L1 capsomeres in the presence of either Kap 1 + RanGDP (A), Kap 1 + RanGDP + p10 (B), Kap
1 + Kap 2 + RanGDP (C), or Kap 1 + Kap 2 + RanGDP + p10 (D). Note the nuclear import in panels
C and D.
|
|
We next tested for nuclear import two GST fusion proteins containing
either the overlapping bipartite/monopartite NLS of HPV16 L1
(GST-bpNLSHPV16L1) or the monopartite NLS of HPV16 L1
(GST-mpNLSHPV16L1). Both the GST-bpNLSHPV16L1
and the GST-mpNLSHPV16L1 were imported into the nucleus in
the presence of cytosol or in the presence of Kap 2 1 heterodimers
plus RanGDP but not in the presence of transport buffer alone or Kap
1 plus RanGDP (Fig. 3 and data not
shown). As a control, GST itself was not imported into the nucleus in
the presence of cytosol (data not shown).

View larger version (92K):
[in this window]
[in a new window]
|
Fig. 3.
Nuclear import of
GST-bpNLSHPV16L1 can be mediated by Kap
2 1 heterodimers.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with GST-bpNLSHPV16L1 in the presence of either
buffer A (A), HeLa cytosol (B), Kap 1 + RanGDP
(C), or Kap 1 + Kap 2 + RanGDP (D). Note
the nuclear import in panels B and D.
|
|
In agreement with the nuclear import data, the bpNLSHPV16L1
interacted directly with Kap 2 (Fig.
4A, lane 1) and
formed a trimeric complex with the Kap 2/Kap 1 heterodimer (Fig.
4A, lane 2). The weak binding of Kap 1 alone
to the GST-bpNLSHPV16L1 (Fig. 4A, lane
3) is assumed to be nonspecific, because it is equivalent to the
interaction of Kap 1 with the GST alone (Fig. 4A,
lane 4). The mpNLSHPV16L1 also interacted
directly with Kap 2 and formed a trimeric complex with the Kap
2/Kap 1 heterodimer (data not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
A, analysis of the interactions between
the bipartite NLS of HPV16 L1 major capsid protein and Kaps.
Immobilized GST-bpNLSHPV16L1 was incubated for 30 min at
room temperature with either Kap 2 (lane 1), Kap 2 + Kap 1 (lane 2), or Kap 1 (lane 3). As a
control, immobilized GST was incubated with Kap 1 (lane
4). B, analysis of the interactions between HPV16 L1
capsomeres and Kap 2 1 heterodimers. Immobilized Kap 1-GST was
incubated with either HPV16 L1 capsomeres alone (lane 1),
the L1 capsomeres plus Kap 2 (lane 2), or the L1
capsomeres plus Kap 2 plus RanGTP (lane 3). Bound
proteins were eluted with sample buffer and analyzed by SDS-PAGE and
Coomassie Blue staining.
|
|
To investigate the direct interactions between HPV16 L1 capsomeres and
Kap 2 1 heterodimers, we used in-solution binding assays with the
GST-Kap 1 immobilized on glutathione-Sepharose beads via the GST
(Fig. 4B). The GST-Kap 1-containing beads were incubated
for 30 min at room temperature with HPV16 L1 capsomeres alone or in the
presence of Kap 2. Binding of HPV16 L1 capsomeres to the Kap
1-containing beads was strongly increased in the presence of Kap
2 (Fig. 4B, compare lanes 1 and 2)
indicating the formation of a complex: L1 capsomere·Kap
2·Kap 1. Moreover, binding of RanGTP to Kap 1 inhibited
binding of the Kap 2·L1 capsomere complex to Kap 1 or
promoted its dissociation (Fig. 4B, compare lanes
2 and 3). These binding results support the nuclear
import data indicating that the Kap 2 1 heterodimers can mediate
nuclear import of HPV16 L1 capsomeres.
Nuclear Import of HPV16 L1 Major Capsid Protein Does Not Require
GTP Hydrolysis by Ran--
Previous studies have suggested that GTP
hydrolysis by Ran is not required for Kap 2 1-mediated nuclear
import of specific cargoes (37, 38). We investigated whether nuclear
import of HPV16 L1 capsomeres and GST-mpNLSHPV16L1 are also
independent of GTP hydrolysis by Ran by comparing their nuclear import
in the presence of Kap 2 plus Kap 1 plus RanGDP and either GTP or
the nonhydrolyzable GTP analogues, GTP S and GMP-PNP. Both HPV16 L1
capsomeres and the GST-mpNLSHPV16L1 were efficiently imported in the presence of either GTP, GTP S, or GMP-PNP (Fig. 5). These data suggest that GTP
hydrolysis by Ran is not required for the nuclear import of HPV16 L1
major capsid protein.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 5.
GTP hydrolysis is not required for Kap
2 1-mediated nuclear import
of HPV16 L1 protein. Digitonin-permeabilized HeLa cells were
incubated for 30 min at room temperature with either HPV16 L1
capsomeres (A-C) or with GST-mpNLSHPV16L1
(D-F) in the presence of Kap 2, Kap 1, and RanGDP.
The added NTPs were as follows: GTP (A and D);
GMP-PNP (B and E); GTP S (C and
F). Note the nuclear import of both HPV16 L1 and
GST-mpNLSHPV16L1 in the presence of either GTP, GMP-PNP, or
GTP S.
|
|
HPV16 L1 Capsomeres Interact with Kap 2 and Inhibit Kap
2-mediated Nuclear Import Pathways--
Human Kap 2/transportin
is known to mediate nuclear import of hnRNP A1 and A2 via interaction
with their Gly/Asn-rich NLS termed M9 (24, 34, 40-43). The yeast
homologue, Kap104p, mediates nuclear import of two abundant nuclear
mRNA binding proteins, Nab2p and Nab4p, via interaction with their
Arg/Gly-rich NLSs (44, 45). We found that HPV16 L1 capsomeres bound
efficiently to human Kap 2 immobilized on glutathione-Sepharose
beads via GST (Fig. 6A,
lane 1). As a control, HPV16 L1 capsomeres did not bind to
the GST immobilized on glutathione-Sepharose beads (Fig. 6A,
lane 3). Surprisingly, binding of RanGTP to Kap 2 had no effect on the interaction between HPV16 L1 capsomeres and Kap 2
(Fig. 6A, compare lanes 1 and 2),
unlike the effect of RanGTP on the L1·Kap 2·Kap 1
interaction. As controls, RanGTP did not bind to the GST itself and was
efficient in inhibiting the interaction between Kap 2 and M9-GST
(data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
HPV16 L1 capsomeres can interact with
Kap 2. A, immobilized Kap
2-GST was incubated at room temperature for 30 min with either HPV16
L1 capsomeres alone (lane 1) or the L1 capsomeres plus
RanGTP (lane 2). As a specificity control, HPV16 L1
capsomeres were incubated with immobilized GST (lane 3).
B, immobilized Kap 2-GST was incubated at room
temperature for 30 min with either HPV16 L1 capsomeres alone
(lane 1) or the L1 capsomeres plus Kap 2 (lane
2). Bound proteins were eluted with sample buffer and analyzed by
SDS-PAGE and Coomassie Blue staining.
|
|
In the presence of Kap 2, the binding of HPV16 L1 capsomeres to Kap
2 was strongly reduced (Fig. 6B, compare lanes
1 and 2), suggesting that Kap 2 competes with Kap
2 for binding to the L1 capsomeres. The bpNLS of HPV16 L1 that
interacts with Kap 2 (Fig. 4A) did not bind to Kap 2
(data not shown). This suggests that the Kap 2-binding site is
either different from the Kap 2-binding site or, if it overlaps with
the Kap 2 site, it is longer.
The interaction between HPV16 L1 capsomeres and Kap 2 prompted us to
investigate whether HPV16 L1 capsomeres can enter into the nucleus via
a Kap 2-mediated pathway. Therefore, digitonin-permeabilized cells
were incubated with either HPV16 L1 capsomeres or the M9-GST-positive control in the presence of Kap 2 plus RanGDP. We observed that Kap
2 plus RanGDP failed to promote nuclear import of HPV16 L1, whereas
the M9-GST control was efficiently localized to the nucleus (data not shown).
Because HPV16 L1 bound to Kap 2 but failed to be imported, we
questioned whether this interaction results in an import incompetent complex that blocks nuclear import of Kap 2. To answer this
question, digitonin-permeabilized HeLa cells were incubated with either GST-Kap 2 or GST-Kap 2 plus RanGDP in the absence or presence of
HPV16 L1 capsomeres. As expected, GST-Kap 2 entered the nucleus either in the absence or presence of RanGDP (Fig.
7A and data not shown).
Interestingly, in the presence of HPV16 L1 capsomeres, nuclear
import of GST-Kap 2 was strongly inhibited (Fig. 7, compare A and B) indicating that binding of HPV16 L1
capsomeres to GST-Kap 2 interferes with nuclear import of GST-Kap
2. In contrast, the weak interaction noted between HPV16 L1
capsomeres and GST-Kap 1 (Fig. 4B) did not inhibit
nuclear import of GST-Kap 1 (data not shown). Significantly, we have
found that, in the presence of HPV16 L1 capsomeres, Kap 2-mediated
nuclear import of its specific M9-GST cargo was inhibited (Fig. 7,
compare C and D). These results suggest that,
although HPV16 L1 capsomeres do not use Kap 2 to enter into the
nucleus, they inhibit Kap 2 nuclear import and, consequently, all
Kap 2-mediated import pathways.

View larger version (111K):
[in this window]
[in a new window]
|
Fig. 7.
HPV16 L1 capsomeres inhibit nuclear import of
Kap 2 and Kap
2-mediated import of M9-GST.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with either GST-Kap 2 (A) or with a mixture
of GST-Kap 2 + 5× molar excess of HPV16 L1 capsomeres that has been
preincubated for 30 min before import (B). Nuclear import of
GST-Kap 2 was detected with an anti-GST antibody.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with either Kap 2 + M9-GST + RanGDP (C) or
with Kap 2 + M9-GST + RanGDP in the presence of HPV16 L1 capsomeres
(in equimolar amounts to the Kap 2) (D). Nuclear import
of M9-GST was detected with an anti-GST antibody.
|
|
The ability of the HPV16 L1 to interact and inhibit nuclear import of
Kap 2 led us to test whether this activity is specific only for the
L1 major capsid protein of high risk HPV16 or if it is shared with the
L1 capsid proteins of other HPV types. We therefore investigated
whether the L1 capsomeres of high risk HPV45 interact with Kap 2 and
found that they did (Fig. 8, lane 1). Moreover, binding of RanGTP to Kap 2 did not dissociate the HPV45 L1·Kap 2 complexes (Fig. 8, lane 2). Also, as for
HPV16 L1 capsomeres, HPV45 L1 capsomeres efficiently inhibited nuclear import of Kap 2 and of its M9-GST cargo (Fig.
9). These data suggest that inhibition of
Kap 2-mediated nuclear import pathways is an activity shared at
least by the L1 major capsid proteins of HPV16 and HPV45.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 8.
HPV45 L1 capsomeres can interact with
Kap 2. A, immobilized Kap
2-GST was incubated at room temperature for 30 min with either HPV45
L1 capsomeres alone (lane 1) or the L1 capsomeres plus
RanGTP (lane 2). As a specificity control, HPV45 L1
capsomeres were incubated with immobilized GST (lane 3).
Bound proteins were eluted with sample buffer and analyzed by SDS-PAGE
and Coomassie Blue staining.
|
|

View larger version (116K):
[in this window]
[in a new window]
|
Fig. 9.
HPV45 L1 capsomeres inhibit nuclear import of
Kap 2 and Kap
2-mediated import of M9-GST.
Digitonin-permeabilized HeLa cells were incubated for 30 min at room
temperature with either GST-Kap 2 (A) or with a mixture
of GST-Kap 2 + 5× molar excess of HPV45 L1 capsomeres that has been
preincubated for 30 min (B). Nuclear import of GST-Kap 2
was detected with an anti-GST antibody. Digitonin-permeabilized HeLa
cells were incubated for 30 min at room temperature with either Kap
2 + M9-GST + RanGDP (C) or Kap 2 + M9-GST + RanGDP in
the presence of HPV45 L1 capsomeres (in equimolar amount to the Kap
2) (D). Nuclear import of M9-GST was detected with an
anti-GST antibody.
|
|
 |
DISCUSSION |
In this study we investigated the nuclear import pathways for the
L1 major capsid protein of high risk HPV16. The nuclear import assays
were carried out in digitonin-permeabilized HeLa cells, which are
commonly used to investigate nuclear import pathways mediated by
different mammalian Kaps (20, 22, 30-38). As previously established
for the L1 major capsid proteins of HPV11 and HPV45 (38, 39), the
intact HPV16 L1 capsids cannot enter the nuclei. This is not surprising
because the capsid diameter (55 nm) is greater than the maximal
functional diameter of the nuclear pore (39 nm) through which active
transport occurs (46). In addition, recent x-ray crystallographic
analysis of 12-capsomere icosahedral particles of HPV16 L1 suggests
that the C terminus of HPV16 L1 might be oriented inside the particle
and not exposed outside the capsid (47). During the import reactions in
digitonin-permeabilized cells in the presence of cytosol it is possible
that the L1 capsomeres might be further disassembled into monomers. The
inability of intact capsids to enter the nuclei would suggest that
during the initial stages of infection disassembly of the capsids would
be required before the nuclear import of incoming L1 proteins can occur. The exposure of incoming HPV capsids to the reducing environment of the cytoplasm could lead to the cleavage of the stabilizing disulfide bonds and, as a consequence, disassembly of the capsids. During the late productive stage of infection the interaction between
the newly synthesized L1 proteins and the corresponding Kaps could
prevent the assembly of L1 into capsids in the cytoplasm. X-ray
crystallographic analysis of 12-capsomere icosahedral particles of
HPV16 L1 indicates that the H4 -helical loop, which is adjacent to
the C-terminal NLS, is involved in intercapsomere interactions (47).
Binding of the one or more corresponding host Kaps to the NLS of HPV16
L1 would interfere with intercapsomere interactions and prevent capsid
assembly in the cytoplasm. Once the L1 proteins enter the nucleus and
are released from their complexes with the Kaps, they can assemble into capsids.
We found that HPV16 L1 capsomeres can interact efficiently with Kap
2 1 heterodimers via Kap 2. The HPV16 L1·Kap 2·Kap 1
complex is translocated through the nuclear pore complex into the
nucleus in the presence of RanGDP and free GTP. In the nucleus, binding
of RanGTP to Kap 1 dissociates the import complex with release of
HPV16 L1·Kap 2. We had previously established that the L1 proteins
of low risk HPV11 and high risk HPV45 can interact with Kap 2 and
enter the nucleus via the classic Kap 2 1-mediated pathway (38,
39). Six Kap isoforms have been identified in higher eukaryotes,
and they all bind to the same Kap 1. The import specificity of Kap
isoforms has been analyzed for proteins containing classic
monopartite and bipartite NLSs (48). When the protein cargoes were
tested singly, they were imported by all six Kap isoforms with
similar efficiencies. The only exception was RCC1, which showed strong
preference for the importin 3 isoform. The import efficiency varied
for Kap isoforms when the protein cargoes were presented
simultaneously (48). Because HPV L1 proteins contain basic monopartite
and/or bipartite NLSs, it is likely that they could interact with other
Kap isoforms in addition to Kap 2 and exploit these interactions
to enter into the nucleus via a classic Kap  1-mediated pathway.
As previously shown for HPV11 L1 and HPV45 L1 capsomeres (38), we
have found that HPV16 L1 capsomeres can also interact with HPV-DNA via
their C-terminal NLSs (data not shown). This would suggest that, during
the late productive stage of viral infection, when the newly
synthesized proteins are imported into the nuclei, the interaction of
L1 with the viral DNA inside the nucleus would favor the release of Kap
2 from the L1·Kap 2 complexes.
In the initial stage of infection the incoming L1 major capsid proteins
are transported into the nuclei of proliferating epithelial cells,
whereas in the late productive phase the newly synthesized L1 proteins
are transported into the nuclei of terminally differentiated keratinocytes. It is not known if there are differences in the expression of different Kaps between the proliferating
versus terminally differentiated epithelial cells. However,
it has been reported that Kap 1, Kap 2 (and other Kap isoforms), and Ran are ubiquitously expressed in various human adult
tissues, with lower levels of Kap 1 found only in spleen and lower
levels of Kap 2 found only in brain and liver (48). This would
suggest that HPV L1 major capsid proteins could enter the nucleus via a
classic Kap  1-mediated pathway during both the initial and late
stage of infection. Although the role of nuclear import of L1 major
capsid proteins in assembling the virions during the late stage of
infection is clearly established, the role of L1 nuclear import during
the initial phase of infection is unclear. It is not known if, after
disassembly of the incoming virions in the cytoplasm, some of the L1
capsomeres would remain associated with the L2 minor capsid protein. If
this is the case the question to be addressed is: do these L1·L2
complexes play a role in facilitating nuclear import of the viral DNA?
Remarkably, we also discovered that the L1 capsomeres of high risk
HPV16 and HPV45 can interact with Kap 2 and inhibit nuclear import
of Kap 2 and of its specific M9-GST cargo. Moreover, preliminary results suggest that the L1 capsomeres of low risk HPV11 share these
activities.2 Together these
data suggest that during the late stage of HPV infection the L1 major
capsid proteins can interact with Kap 2 and inhibit Kap
2-mediated nuclear import pathways of the host epithelial cells. The
main cargoes transported by Kap 2 are hnRNP A1 and A2, and the
interaction with Kap 2 is mediated by the shuttling sequence M9 (24,
34, 40-43). It has been shown that nucleocytoplasmic shuttling of
hnRNP A1 is strongly correlated with mRNA nuclear export (49).
Hence, in the late stage of viral infection the interaction of newly
synthesized L1 proteins with Kap 2 may inhibit Kap 2-mediated
nuclear import of hnRNP A1 and, as a consequence, affect mRNA
nuclear export. As HPV L1 capsomeres are efficiently imported into the
nuclei of digitonin-permeabilized cells in the presence of HeLa
cytosol, the higher affinity interaction of L1 capsomeres is with Kap
2 1 heterodimers leading to nuclear import. This is in agreement
with the fact that Kap 2 competed with Kap 2 for binding to HPV16
L1 capsomeres (Fig. 6B) and with the immunoisolation assays
with HPV45 L1 capsomeres in which Kap 2, but not Kap 2, was
isolated (38). This suggests that, during the late phase of the viral
life cycle, when the L1 proteins are synthesized, some of the L1
proteins could interact with Kap 2 and inhibit Kap 2-mediated
nuclear import of hnRNP A1 and, consequently, affect mRNA export.
Because little is known about the stoichiometry of L1 capsomere levels
versus Kap 2 1 heterodimers and Kap 2 during
different stages of HPV infection, further studies in vivo are required to analyze if L1 major capsid proteins inhibit the nuclear
import of hnRNP A1 and A2 during the late stage of the viral life cycle.
The interaction of HPV L1 major capsid proteins with Kap 2 raises
the question of whether L1 proteins interact with additional members of
the Kap family. Preliminary data indicate that HPV16 L1 can also
interact with Kap 3 and inhibit Kap 3 nuclear import. This
suggests that HPV L1 major capsid proteins could also interact with
other members of the Kap superfamily and, perhaps, inhibit other
major nuclear import pathways of host cells.
There are many studies demonstrating that viruses exploit the nuclear
import pathways of host cells for entry of their macromolecules into
the nucleus. However, only a few examples of viral infections that
inhibit nuclear import and/or export pathways of host cells have been
reported. Poliovirus infection inhibits nuclear import of hnRNP A1, K,
and C causing their relocalization in the cytoplasm. The mechanism of
inhibition seems to involve the proteolytic degradation of Nup153 and
p62, affecting traffic through the nuclear pore complex (50). Also, the
matrix protein of the vesicular stomatitis virus inhibits different
nuclear import and export pathways, and the inhibitory effect of the
matrix protein seems to involve binding to the nucleoplasmic
nucleoporin Nup98 (51, 52). In both cases the viruses are targeting
components of the nuclear pore complex. We propose that the strategy
used by HPVs involves targeting the import receptor, Kap 2, and
blocking Kap 2-mediated nuclear import of hnRNP A1 and A2. Further
studies are required to understand the role of inhibition of Kap
2-mediated nuclear import pathways of host cells during the late
stage of infection when the virions are formed and released.
 |
ACKNOWLEDGEMENTS |
We thank Drs. G. Blobel, Y. M. Chook, K. Weis, A. Lamond, S. Adam, and G. Dreyfuss for their generous gift of
expression vectors. We thank C. Lane, P. Felice, M. Angeline, and A. Rich for technical assistance in the preparation of HPV16/45 L1 capsids
and recombinant transport factors and E. Merle for help in the
preparation of figures. We thank Drs. A. Annunziato and Y. M. Chook for helpful discussions and Dr. C. Hoffman for critical reading
of the manuscript.
 |
FOOTNOTES |
*
This work was supported by Grant RPG-99-210-01-MBC from the
American Cancer Society (to J. M.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
617-552-1713; Fax: 617-552-2011; E-mail: moroianu@bc.edu.
Published, JBC Papers in Press, April 23, 2002, DOI 10.1074/jbc.M200724200
2
L. M. Nelson, R. C. Rose, and J. Moroianu, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
HPV, human
papillomavirus;
NLS, nuclear localization signal;
GST, glutathione
S-transferase;
GTP S, guanosine
5'-O-(thiotriphosphate);
GMP-PNP, guanylyl imidodiphosphate;
hnRNP, heterogeneous nuclear ribonucleoprotein;
IPTG, isopropyl-1-thio- -D-galactopyranoside;
mpNLS, monopartite NLS;
bpNLS, bipartite/monopartite NLS;
NPC, nuclear pore
complex.
 |
REFERENCES |
| 1.
|
zur Hausen, H.
(2000)
J. Natl. Cancer Inst.
92,
690-698[Abstract/Free Full Text]
|
| 2.
|
Doorbar, J.,
and Gallimore, P. H.
(1987)
J. Virol.
61,
2793-2799[Abstract/Free Full Text]
|
| 3.
|
Trus, B. L.,
Roden, R. B.,
Greenstone, H. L.,
Vrhel, M.,
Schiller, J. T.,
and Booy, F. P.
(1997)
Nat. Struct. Biol.
4,
413-420[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Kirnbauer, R.,
Booy, F.,
Cheng, N.,
Lowy, D. R.,
and Schiller, J. T.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
12180-12184[Abstract/Free Full Text]
|
| 5.
|
Rose, R. C.,
Bonnez, W.,
Reichman, R. C.,
and Garcea, R. L.
(1993)
J. Virol.
67,
1936-1944[Abstract/Free Full Text]
|
| 6.
|
Zhou, J.,
Stenzel, D. J.,
Sun, X. Y.,
and Frazer, I. H.
(1993)
J. Gen. Virol.
74,
763-768[Abstract/Free Full Text]
|
| 7.
|
Hagensee, M. E.,
Olson, N. H.,
Baker, T. S.,
and Galloway, D. A.
(1994)
J. Virol.
68,
4503-4505[Abstract/Free Full Text]
|
| 8.
|
Volpers, C.,
Schirmacher, P.,
Streeck, R. E.,
and Sapp, M.
(1994)
Virology
200,
504-512[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Belnap, D. M.,
Olson, N. H.,
Cladel, N. M.,
Newcomb, W. W.,
Brown, J. C.,
Kreider, J. W.,
Christensen, N. D.,
and Baker, T. S.
(1996)
J. Mol. Biol.
259,
249-263[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Li, M.,
Beard, P.,
Estes, P. A.,
Lyon, M. K.,
and Garcea, R. L.
(1998)
J. Virol.
72,
2160-2167[Abstract/Free Full Text]
|
| 11.
|
McCarthy, M. P.,
White, W. I.,
Palmer-Hill, F.,
Koenig, S.,
and Suzich, J. A.
(1998)
J. Virol.
72,
32-41[Abstract/Free Full Text]
|
| 12.
|
Nakielny, S.,
and Dreyfuss, G.
(1999)
Cell
99,
677-690[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Moroianu, J.
(1999)
J. Cell. Biochem.
32-33 (suppl.),
76-83
|
| 14.
|
Wente, S. R.
(2000)
Science
288,
1374-1377[Abstract/Free Full Text]
|
| 15.
|
Gorlich, D.,
Prehn, S.,
Laskey, R. A.,
and Hartmann, E.
(1994)
Cell
79,
767-778[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Gorlich, D.,
Kostka, S.,
Kraft, R.,
Dingwall, C.,
Laskey, R. A.,
Hartmann, E.,
and Prehn, S.
(1995)
Curr. Biol.
5,
383-392[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Radu, A.,
Blobel, G.,
and Moore, M. S.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1769-1773[Abstract/Free Full Text]
|
| 18.
|
Moroianu, J.,
Hijikata, M.,
Blobel, G.,
and Radu, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6532-6536[Abstract/Free Full Text]
|
| 19.
|
Moroianu, J.,
Blobel, G.,
and Radu, A.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
2008-2011[Abstract/Free Full Text]
|
| 20.
|
Weis, K.,
Mattaj, I. W.,
and Lamond, A. I.
(1995)
Science
268,
1049-1053[Abstract/Free Full Text]
|
| 21.
|
Imamoto, N.,
Shimamoto, T.,
Takao, T.,
Tachibana, T.,
Kose, S.,
Matsubae, M.,
Sekimoto, T.,
Shimonishi, Y.,
and Yoneda, Y.
(1995)
EMBO J.
14,
3617-3626[Medline]
[Order article via Infotrieve]
|
| 22.
|
Ribbeck, K.,
Lipowsky, G.,
Kent, H. M.,
Stewart, M.,
and Gorlich, D.
(1998)
EMBO J.
17,
6587-6598[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Chi, N. C.,
Adam, E. J.,
Visser, G. D.,
and Adam, S. A.
(1996)
J. Cell Biol.
135,
559-569[Abstract/Free Full Text]
|
| 24.
|
Chook, Y. M.,
and Blobel, G.
(1999)
Nature
399,
230-237[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Coutavas, E.,
Ren, M.,
Oppenheim, J. D.,
D'Eustachio, P.,
and Rush, M. G.
(1993)
Nature
366,
585-587[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Floer, M.,
and Blobel, G.
(1996)
J. Biol. Chem.
271,
5313-5316[Abstract/Free Full Text]
|
| 27.
|
Rose, R. C.,
Bonnez, W., Da,
Rin, C.,
McCance, D. J.,
and Reichman, R. C.
(1994)
J. Gen. Virol.
75,
2445-2449[Abstract/Free Full Text]
|
| 28.
|
Rose, R. C.,
Reichman, R. C.,
and Bonnez, W.
(1994)
J. Gen. Virol.
75,
2075-2079[Abstract/Free Full Text]
|
| 29.
|
Zhou, J.,
Doorbar, J.,
Sun, X. Y.,
Crawford, L. V.,
McLean, C. S.,
and Frazer, I. H.
(1991)
Virology
185,
625-632[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Adam, E. J.,
and Adam, S. A.
(1994)
J. Cell Biol.
125,
547-555[Abstract/Free Full Text]
|
| 31.
|
Chi, N. C.,
Adam, E. J.,
and Adam, S. A.
(1995)
J. Cell Biol.
130,
265-274[Abstract/Free Full Text]
|
| 32.
|
Gorlich, D.,
Vogel, F.,
Mills, A. D.,
Hartmann, E.,
and Laskey, R. A.
(1995)
Nature
377,
246-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Paschal, B. M.,
and Gerace, L.
(1995)
J. Cell Biol.
129,
925-937[Abstract/Free Full Text]
|
| 34.
|
Pollard, V. W.,
Michael, W. M.,
Nakielny, S.,
Siomi, M. C.,
Wang, F.,
and Dreyfuss, G.
(1996)
Cell
86,
985-994[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Kataoka, N.,
Bachorik, J. L.,
and Dreyfuss, G.
(1999)
J. Cell Biol.
145,
1145-1152[Abstract/Free Full Text]
|
| 36.
|
Ribbeck, K.,
Kutay, U.,
Paraskeva, E.,
and Gorlich, D.
(1999)
Curr. Biol.
9,
47-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Schwoebel, E. D.,
Talcott, B.,
Cushman, I.,
and Moore, M. S.
(1998)
J. Biol. Chem.
273,
35170-35175[Abstract/Free Full Text]
|
| 38.
|
Nelson, L. M.,
Rose, R. C.,
LeRoux, L.,
Lane, C.,
Bruya, K.,
and Moroianu, J.
(2000)
J. Cell. Biochem.
79,
225-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Merle, E.,
Rose, R. C.,
LeRoux, L.,
and Moroianu, J.
(1999)
J. Cell. Biochem.
74,
628-637[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Michael, W. M.,
Choi, M.,
and Dreyfuss, G.
(1995)
Cell
83,
415-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Siomi, H.,
and Dreyfuss, G.
(1995)
J. Cell Biol.
129,
551-560[Abstract/Free Full Text]
|
| 42.
|
Bonifaci, N.,
Moroianu, J.,
Radu, A.,
and Blobel, G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5055-5060[Abstract/Free Full Text]
|
| 43.
|
Siomi, M. C.,
Eder, P. S.,
Kataoka, N.,
Wan, L.,
Liu, Q.,
and Dreyfuss, G.
(1997)
J. Cell Biol.
138,
1181-1192[Abstract/Free Full Text]
|
| 44.
|
Lee, D. C.,
and Aitchison, J. D.
(1999)
J. Biol. Chem.
274,
29031-29037[Abstract/Free Full Text]
|
| 45.
|
Aitchison, J. D.,
Blobel, G.,
and Rout, M. P.
(1996)
Science
274,
624-627[Abstract/Free Full Text]
|
| 46.
|
Pante, N.,
and Kann, M.
(2002)
Mol. Biol. Cell
13,
425-434[Abstract/Free Full Text]
|
| 47.
|
Chen, X. S.,
Garcea, R. L.,
Goldberg, I.,
Casini, G.,
and Harrison, S. C.
(2000)
Mol. Cell
5,
557-567[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Kohler, M.,
Speck, C.,
Christiansen, M.,
Bischoff, F. R.,
Prehn, S.,
Haller, H.,
Gorlich, D.,
and Hartmann, E.
(1999)
Mol. Cell. Biol.
19,
7782-7791[Abstract/Free Full Text]
|
| 49.
|
Izaurralde, E.,
Jarmolowski, A.,
Beisel, C.,
Mattaj, I. W.,
Dreyfuss, G.,
and Fischer, U.
(1997)
J. Cell Biol.
137,
27-35[Abstract/Free Full Text]
|
| 50.
|
Gustin, K. E.,
and Sarnow, P.
(2001)
EMBO J.
20,
240-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Her, L. S.,
Lund, E.,
and Dahlberg, J. E.
(1997)
Science
276,
1845-1848[Abstract/Free Full Text]
|
| 52.
|
von Kobbe, C.,
van Deursen, J. M.,
Rodrigues, J. P.,
Sitterlin, D.,
Bachi, A., Wu, X.,
Wilm, M.,
Carmo-Fonseca, M.,
and Izaurralde, E.
(2000)
Mol. Cell
6,
1243-1252[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Bird, M. O'Donnell, J. Moroianu, and R. L. Garcea
Possible Role for Cellular Karyopherins in Regulating Polyomavirus and Papillomavirus Capsid Assembly
J. Virol.,
October 15, 2008;
82(20):
9848 - 9857.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Yu, A. Bashirova, M. M. Madeleine, J. Cheng, L. G. Johnson, S. M. Schwartz, M. Carrington, and A. Hildesheim
Evaluation of the Association with Cervical Cancer of Polymorphisms in Syndecan-1, a Heparan Sulfate Proteoglycan Involved with Viral Cell Entry
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2007;
16(11):
2504 - 2508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-L. Bian, G. Rosas-Acosta, Y.-C. Wu, and V. G. Wilson
Nuclear Import of Bovine Papillomavirus Type 1 E1 Protein Is Mediated by Multiple Alpha Importins and Is Negatively Regulated by Phosphorylation near a Nuclear Localization Signal
J. Virol.,
March 15, 2007;
81(6):
2899 - 2908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bordeaux, S. Forte, E. Harding, M. S. Darshan, K. Klucevsek, and J. Moroianu
The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA.
J. Virol.,
August 1, 2006;
80(16):
8259 - 8262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Stallings and S. Silverstein
Dissection of a Novel Nuclear Localization Signal in Open Reading Frame 29 of Varicella-Zoster Virus
J. Virol.,
October 15, 2005;
79(20):
13070 - 13081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Darshan, J. Lucchi, E. Harding, and J. Moroianu
The L2 Minor Capsid Protein of Human Papillomavirus Type 16 Interacts with a Network of Nuclear Import Receptors
J. Virol.,
November 15, 2004;
78(22):
12179 - 12188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Bousarghin, A. Touze, P.-Y. Sizaret, and P. Coursaget
Human Papillomavirus Types 16, 31, and 58 Use Different Endocytosis Pathways To Enter Cells
J. Virol.,
March 15, 2003;
77(6):
3846 - 3850.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. G. Le Roux and J. Moroianu
Nuclear Entry of High-Risk Human Papillomavirus Type 16 E6 Oncoprotein Occurs via Several Pathways
J. Virol.,
February 15, 2003;
77(4):
2330 - 2337.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|